Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

References

• American Diabetes Association Standards of medical care in diabetes-2015 Diabetes Care 2015 38 Suppl 1 S1 S93
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation IDF Diabetes Atlas 7th Ed 2015 Available from: http://www.diabetesatlas.org/resources/2015-atlas.html Accessed January 31, 2017
   Google Scholar
• Mathers CD Loncar D Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 2006 3 11 e442 17132052
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Pfeffer MA Claggett B Diaz R ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 2015 373 23 2247 2257 26630143
   PubMed Web of Science ®Google Scholar
• Berg JK Shenouda SK Heilmann CR Gray AL Holcombe JH Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study Diabetes Obes Metab 2011 13 11 982 989 21615670
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C Macconell L DURATION-2 Study Group Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M DURATION-4 Study Group Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Nauck M Weinstock RS Umpierrez GE Guerci B Skrivanek Z Milicevic Z Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care 2014 37 8 2149 2158 24742660
   PubMed Web of Science ®Google Scholar
• Weinstock RS Guerci B Umpierrez G Nauck MA Skrivanek Z Milicevic Z Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study Diabetes Obes Metab 2015 17 9 849 858 25912221
   PubMed Web of Science ®Google Scholar
• Charbonnel B Steinberg H Eymard E Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial Diabetologia 2013 56 7 1503 1511 23604551
   PubMed Web of Science ®Google Scholar
• Pratley R Nauck M Bailey T 1860-LIRA-DPP-4 Study Group One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 2011 65 4 397 407 21355967
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck M Bailey T 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 2010 375 9724 1447 1456 20417856
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck MA Bailey T 1860-LIRA-DPP-4 Study Group Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial Diabetes Care 2012 35 10 1986 1993 22851600
   PubMed Web of Science ®Google Scholar
• Takeshita Y Takamura T Kita Y Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study J Diabetes Investig 2015 6 2 192 200
   Web of Science ®Google Scholar
• Van Gaal L Souhami E Zhou T Aronson R Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus J Clin Transl Endocrinol 2014 1 2 31 37
   Google Scholar
• Horton ES Silberman C Davis KL Berria R Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database Diabetes Care 2010 33 8 1759 1765 20460445
   PubMed Web of Science ®Google Scholar
• Montilla S Marchesini G Sammarco A AIFA Anti-diabetics Monitoring Group Drug utilization, safety, and effectiveness of exena-tide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry Nutr Metab Cardiovasc Dis 2014 24 12 1346 1353 25300980
   PubMed Web of Science ®Google Scholar
• Nyeland ME Ploug UJ Richards A Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care Int J Clin Pract 2015 69 3 281 291 25302822
   PubMed Web of Science ®Google Scholar
• Umpierrez G Tofé Povedano S Pérez Manghi F Shurzinske L Pechtner V Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 2014 37 8 2168 2176 24842985
   PubMed Web of Science ®Google Scholar
• Derosa G Maffioli P Salvadeo SA Exenatide versus glibenclamide in patients with diabetes Diabetes Technol Ther 2010 12 3 233 240 20151774
   PubMed Web of Science ®Google Scholar
• Derosa G Putignano P Bossi AC Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients Eur J Pharmacol 2011 666 1–3 251 256 21645507
   PubMed Web of Science ®Google Scholar
• Gallwitz B Guzman J Dotta F Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial Lancet 2012 379 9833 2270 2278 22683137
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 9662 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Garber A Henry RR Ratner R Hale P Chang CT Bode B LEAD-3 (Mono) Study Group Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycae-mic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 2011 13 4 348 356 21205128
   PubMed Web of Science ®Google Scholar
• Kaku K Rasmussen MF Nishida T Seino Y Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes J Diabetes Investig 2011 2 6 441 447
   Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study Diabetes Obes Metab 2013 15 3 204 212 22985213
   PubMed Web of Science ®Google Scholar
• Nauck M Marre M Adding liraglutide to oral antidiabetic drug mono-therapy: efficacy and weight benefits Postgrad Med 2009 121 3 5 15
   PubMed Web of Science ®Google Scholar
• Seino Y Rasmussen MF Nishida T Kaku K Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes Curr Med Res Opin 2010 26 5 1013 1022 20199137
   PubMed Web of Science ®Google Scholar
• Chiefari E Capula C Vero A Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy Diabetes Technol Ther 2015 17 7 468 474 25844858
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglu-tide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brändle M LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 3 268 278 19317822
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Triplitt C Qu Y Lewis MS Maggs D Glass LC Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin Diabetes Care 2010 33 5 951 957 20107105
   PubMed Web of Science ®Google Scholar
• Xu W Bi Y Sun Z Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study) J Intern Med 2015 277 1 137 150 25039675
   PubMed Web of Science ®Google Scholar
• Araki E Inagaki N Tanizawa Y Oura T Takeuchi M Imaoka T Efficacy and safety of once-weekly dulaglutide in combination with sulpho-nylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study Diabetes Obes Metab 2015 17 10 994 1002 26179754
   PubMed Web of Science ®Google Scholar
• Barnett AH Burger J Johns D Tolerability and efficacy of exena-tide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial Clin Ther 2007 29 11 2333 2348 18158075
   PubMed Web of Science ®Google Scholar
• Bergenstal R Lewin A Bailey T Chang D Gylvin T Roberts V Novo-Log Mix-vs.-Exenatide Study Group Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea Curr Med Res Opin 2009 25 1 65 75 19210140
   PubMed Web of Science ®Google Scholar
• Blonde L Jendle J Gross J Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study Lancet 2015 385 9982 2057 2066 26009229
   PubMed Web of Science ®Google Scholar
• D’Alessio D Häring HU Charbonnel B EAGLE Investigators Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes Diabetes Obes Metab 2015 17 2 170 178 25359159
   PubMed Web of Science ®Google Scholar
• Davies M Heller S Sreenan S Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas Diabetes Care 2013 36 5 1368 1376 23275363
   PubMed Web of Science ®Google Scholar
• Davies MJ Donnelly R Barnett AH Jones S Nicolay C Kilcoyne A Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study Diabetes Obes Metab 2009 11 12 1153 1162 19930005
   PubMed Web of Science ®Google Scholar
• Diamant M Nauck MA Shaginian R 4B Study Group Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes Diabetes Care 2014 37 10 2763 2773 25011946
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Guerci B Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial Lancet Diabetes Endocrinol 2014 2 6 464 473 24731672
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks Diabetes Care 2012 35 4 683 689 22357185
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Gallwitz B Böhmer M Segiet T Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia Diabetes Care 2011 34 3 604 606 21285388
   PubMed Web of Science ®Google Scholar
• Giorgino F Benroubi M Sun JH Zimmermann AG Pechtner V Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) Diabetes Care 2015 38 12 2241 2249 26089386
   PubMed Web of Science ®Google Scholar
• Gough SC Bode BW Woo VC One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial Diabetes Obes Metab 2015 17 10 965 973 25980900
   PubMed Web of Science ®Google Scholar
• Gough SCL Bode B Woo V NN9068-3697 (DUAL-I) trial investigators Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes Lancet Diabetes Endocrinol 2014 2 11 885 893 25190523
   PubMed Web of Science ®Google Scholar
• Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG GWAA Study Group Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2005 143 8 559 569 16230722
   PubMed Web of Science ®Google Scholar
• Inagaki N Atsumi Y Oura T Saito H Imaoka T Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral anti-diabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clin Ther 2012 34 9 1892 1908 22884767
   PubMed Web of Science ®Google Scholar
• Mathieu C Ostenson CG Matthaei S Using exenatide twice daily or insulin in clinical practice: results from CHOICE Diabetes Ther 2013 4 2 285 308 24018835
   PubMed Web of Science ®Google Scholar
• Mathieu C Rodbard HW Cariou B BEGIN: VICTOZA ADD-ON (NN1250-3948) study group A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON) Diabetes Obes Metab 2014 16 7 636 644 24443830
   PubMed Web of Science ®Google Scholar
• Nauck MA Duran S Kim D A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Diabetologia 2007 50 2 259 267 17160407
   PubMed Web of Science ®Google Scholar
• Ostenson CG Matthaei S Reaney M Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries Diabetes Metab Syndr Obes 2013 6 171 185 23667315
   PubMedGoogle Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 2009 52 10 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Baser O Wei W Baser E Xie L Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID J Med Econ 2011 14 6 673 680 21892858
   PubMedGoogle Scholar
• Bounthavong M Tran JN Golshan S Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes Diabetes Metab 2014 40 4 284 291 25059703
   PubMed Web of Science ®Google Scholar
• Dalal MR Xie L Baser O DiGenio A Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: outcomes in a community setting Endocr Pract 2015 21 1 68 76 25148821
   PubMed Web of Science ®Google Scholar
• Pawaskar M Li Q Hoogwerf BJ Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting Diabetes Obes Metab 2012 14 7 626 633 22321776
   PubMed Web of Science ®Google Scholar
• Pawaskar M Li Q Reynolds MW Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting Curr Med Res Opin 2012 28 6 991 997 22519390
   PubMed Web of Science ®Google Scholar
• Sudhakaran C Fathima M Anjana RM Unnikrishnan RI Mohan V Effectiveness of exenatide in Asian Indians in a clinical care setting Diabetes Technol Ther 2010 12 8 613 618 20615102
   PubMed Web of Science ®Google Scholar
• Reid T Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence Clin Diabetes 2012 30 1 3 12
   Google Scholar
• Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 4 470 512 19074620
   PubMed Web of Science ®Google Scholar
• Smilowitz NR Donnino R Schwartzbard A Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease Circulation 2014 129 22 2305 2312 24891623
   PubMed Web of Science ®Google Scholar
• Lang K Nguyen H Huang H Kaufman E Levin P Real-world treatment responses from electronic medical record (EMR) data among patients with type 2 diabetes (T2D) receiving basal insulin either with mealtime insulin or exenatide BID, by A1c attainment level and baseline A1c [abstract 1540-P] Diabetes 2016 65 Suppl 1 A360 A431
   Google Scholar
• Lorenz M Lawson F Owens D Differential effects of glucagon-like peptide-1 receptor agonists on heart rate Cardiovasc Diabetol 2017 16 1 6 28086882
   PubMed Web of Science ®Google Scholar
• Marso SP Bain SC Consoli A SUSTAIN-6 Investigators Sema-glutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2016 375 19 1834 1844 27633186
   PubMed Web of Science ®Google Scholar
• Bentley-Lewis R Aguilar D Riddle MC ELIXA Investigators Rationale, design, and baseline characteristics in Evaluation of LIX-isenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo Am Heart J 2015 169 5 631 638 25965710
   PubMed Web of Science ®Google Scholar
• Holman RR Bethel MA George J Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial Am Heart J 2016 174 103 110 26995376
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) ClinicalTrials.gov record: NCT01394952. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952 Accessed October 11, 2016
   Google Scholar
• GlaxoSmithKline A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with type 2 diabetes mellitus (HARMONY Outcomes) ClinicalTrials.gov identifier: NCT02465515. Available from: https://clinicaltrials.gov/ct2/show/NCT02465515 Accessed October 11, 2016
   Google Scholar
• Ferdinand KC Botros FT Atisso CM Sager PT Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events Cardiovasc Diabetol 2016 15 38 26912057
   PubMed Web of Science ®Google Scholar
• Fisher M Petrie MC Ambery PD Donaldson J Ye J McMurray JJ Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis Lancet Diabetes Endocrinol 2015 3 9 697 703 26276240
   PubMed Web of Science ®Google Scholar
• Ratner R Han J Nicewarner D Yushmanova I Hoogwerf BJ Shen L Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes Cardiovasc Diabetol 2011 10 22 21410975
   PubMed Web of Science ®Google Scholar
• Monami M Cremasco F Lamanna C Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials Exp Diabetes Res 2011 2011 215764 21584276
   PubMedGoogle Scholar
• Monami M Dicembrini I Nardini C Fiordelli I Mannucci E Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2014 16 1 38 47 23829656
   PubMed Web of Science ®Google Scholar
• Wu S Sun F Zhang Y The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials J Clin Pharm Ther 2014 39 1 7 13 24127768
   PubMed Web of Science ®Google Scholar
• Patorno E Everett BM Goldfine AB Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other anti-diabetic drugs in routine care: a cohort study Diabetes Obes Metab 2016 18 8 755 765 27003762
   PubMed Web of Science ®Google Scholar
• Paul SK Klein K Maggs D Best JH The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study Cardiovasc Diabetol 2015 14 10 25616979
   PubMed Web of Science ®Google Scholar
• Best JH Hoogwerf BJ Herman WH Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 2011 34 1 90 95 20929995
   PubMed Web of Science ®Google Scholar